Friday, 16 October 2026European Markets

POLARIS MEDIA Stock Was 19.3% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with POLARIS MEDIA (POL.OL) rising 19.3% to kr68.00 on Wednesday while Oslo Børs Benchmark Index_GI dropped 0.14% to kr1,289.59.

POLARIS MEDIA's last close was kr57.00, 10.94% below its 52-week high of kr64.00.

About POLARIS MEDIA

Polaris Media ASA operates as a media house and printing company in Norway and Sweden. The company provides digital advertising services. It also prints group and external newspapers, including editorial supplements, advertising supplements and newspapers, civil prints, and other magazines/supplements. In addition, the company distributes newspapers, as well as parcels, mails, and food deliveries. The company was founded in 2008 and is headquartered in Trondheim, Norway.

Earnings Per Share

As for profitability, POLARIS MEDIA has a trailing twelve months EPS of kr0.27.

PE Ratio

POLARIS MEDIA has a trailing twelve months price to earnings ratio of 251.85. Meaning, the purchaser of the share is investing kr251.85 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 0.47%.

More news about POLARIS MEDIA (POL.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com